News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Salix Pharmaceuticals, Ltd. (SLXP) Commences Cash Tender Offer For All Outstanding Shares Of Santarus Inc. (SNTS)



12/3/2013 8:57:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix”) today announced the commencement of a cash tender offer by its indirect wholly owned subsidiary, Willow Acquisition Sub Corporation (“Purchaser”), to purchase all of the issued and outstanding shares of common stock, par value $0.0001 per share, of Santarus, Inc. (NASDAQ:SNTS) (“Santarus”) at a purchase price of $32.00 per share, net to the seller in cash, without interest and subject to any required withholding taxes. The tender offer is being made pursuant to an Offer to Purchase, dated December 3, 2013, and in connection with the previously announced definitive merger agreement, dated November 7, 2013, among Salix, Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Salix (“Intermediary”), Purchaser and Santarus.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES